The so-called “butterfly skin”, as epidermolysis bullosa is popularly known, is one of those diseases that force us to take a hard look at the reality of our healthcare systems. It is a devastating genetic disorder: the skin breaks at the slightest touch, causing constant wounds, chronic pain and a high risk of infections and serious complications. For decades, only palliative treatments were available. Today, thanks to advances in gene therapy, there are drugs that can dramatically improve healing and the quality of life of patients.
But there is a problem: although these therapies have been approved in Europe, not all European patients have access to them.
This is one of the great contradictions of the European project. The European Union boasts a common framework of health regulation and shared scientific decisions. When the European Medicines Agency approves a treatment, it does so after rigorously assessing its efficacy and safety for all European citizens. However, the reality is that this approval does not guarantee that the medicine will reach patients. Each country then decides whether and when to fund it.
In practice, this means that one patient can receive an innovative therapy in Germany or France while another, in Spain, has to wait years for a price negotiation to be resolved. This is not a scientific issue, but an economic one.
The official argument is the sustainability of the healthcare system. New therapies for rare diseases are extremely expensive, and governments must negotiate with pharmaceutical companies to prevent public spending from skyrocketing. That debate is legitimate. But what is increasingly difficult to justify is the real hierarchy of priorities.
For while it is discussed for years whether a treatment that can alleviate the suffering of a handful of patients is “too expensive”, public money flows with surprising ease into other areas: large armament programmes, financial bailouts, institutional events or political ceremonies whose social impact is, to say the least, debatable.
This is not a problem unique to Spain. It is a broader symptom of a Europe that too often functions more like a club of economic interests than a true political and social community. Joint decisions are taken when it suits the market, but when it comes to fundamental issues - such as public health or equitable access to treatment - each state acts on its own.
The result is a silent inequality between citizens who, in theory, share the same political space.
Rare diseases demonstrate this contradiction in a particularly cruel way. Because they affect few patients, they are often left out of major budgetary priorities. Yet this is precisely why they should be a test of the ethical commitment of our societies. A healthcare system is measured not only by how it treats the majority, but also by how it protects the most vulnerable.
The underlying issue is simple: it is not that Europe or Spain cannot afford certain treatments. It is that, on too many occasions, we choose to spend public money on other things.
Last week, this reality was exposed in a way that was as simple as it was uncomfortable. A 12-year-old boy from Seville addressed the European Parliament to ask for something that should be obvious: the right to receive the same treatment as other European children with the same disease. His intervention was not a political speech, but a direct appeal to the coherence of a system that proclaims equality while tolerating health inequalities within its own borders.
This case also opens up another necessary debate: the role of the pharmaceutical industry. It is indisputable that the development of innovative therapies requires huge investments in research. But when it comes to life-saving drugs for rare and extremely serious diseases, perhaps it is also time to consider reasonable limits to profit margins.
No one chooses to be born with a devastating genetic disease. And when survival or dignity of life depends on treatment, access should not become a market issue.
Perhaps even the pricing model for medicines needs to be rethought. It is paradoxical that essential therapies for rare diseases reach multi-million dollar figures while other drugs associated with problems arising from risky behaviour - such as certain addictions or avoidable excesses - do not face the same social debate about their cost.
Reordering priorities does not mean denying the complexity of health systems or of pharmaceutical innovation. It means remembering what should be at the heart of public decisions.
In a context marked by geopolitical tensions, increased military spending and shifting economic priorities, it is worth remembering that the pillars of any democratic society remain the same: health, education and social welfare.
True progress is not measured by the ability to finance conflicts or ceremonies, but by the will to protect the lives and dignity of citizens.
Butterfly skin is a rare disease. But the debate it raises about our collective priorities is anything but rare.
